Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial

Plasma tumor DNA dynamics provide an early indication of docetaxel effectiveness. The liquid biopsy resistance biomarker identifies patients who benefit from continuing enzalutamide after progression when combined with docetaxel. The findings highlight cell cycle gene alterations as a potential caus...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European urology oncology 2024-09
Hauptverfasser:	Ruiz-Vico, Maria, Wetterskog, Daniel, Orlando, Francesco, Thakali, Suparna, Wingate, Anna, Jayaram, Anuradha, Cremaschi, Paolo, Vainauskas, Osvaldas, Brighi, Nicole, Castellano-Gauna, Daniel, Åström, Lennart, Matveev, Vsevolod B., Bracarda, Sergio, Esen, Adil, Feyerabend, Susan, Senkus, Elżbieta, López-Brea Piqueras, Marta, Gupta, Santosh, Wenstrup, Rick, Boysen, Gunther, Martins, Karla, Iwata, Kenneth, Chowdhury, Simon, Gourgioti, Georgia, Serikoff, Alexis, Gonzalez-Billalabeitia, Enrique, Merseburger, Axel S., Demichelis, Francesca, Attard, Gerhardt
Format:	Artikel
Sprache:	eng
Schlagworte:	Androgen receptor gain Androgen receptor splice variants Circulating tumor cells Docetaxel Enzalutamide Liquid biopsy resistance biomarker Metastatic castration-resistant prostate cancer Plasma circulating tumor DNA PRESIDE trial
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!